Home
|
Job Seekers
|
Employers
|
FAQ
|
Contact Us
You're not logged in!
Login
|
Job Search
|
Job Seeker Register
|
Employer Register
|
Translate:
Select Language
English Version to Apply
Spanish
Chinese
French
Watson Pharmaceuticals Jobs
Click links to read Current News for this Featured Employer
Watson to Present at Credit Suisse Healthcare Conference
|
Watson Reports Third Quarter 2009 GAAP EPS of $0.55; Adjusted EPS of $0.66
|
Watson Names R. Todd Joyce Senior Vice President and Chief Financial Officer; Succeeds Mark W. Durand
|
Watson Announces Offering of Senior Unsecured Notes
|
Watson Prices $850 Million of Senior Unsecured Notes
|
Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
|
Watson CFO Mark W. Durand to Take Leave of Absence
|
Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast
|
Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
|
Watson Provides Update on Ferrlecit(R) Supply and Distribution Agreement
|
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
|
Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
|
/C O R R E C T I O N -- Watson Pharmaceuticals, Inc./
|
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
|
Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
|
Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
|
Watson Pharmaceuticals Receives FDA Approval for Generic Razadyne(R) ER Capsules
|
Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer
|
Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference
|
Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
|
/C O R R E C T I O N -- Watson Pharmaceuticals, Inc./
|
Watson Pharmaceuticals Reports Second Quarter 2008 Results
|
Items 1-16/16 displayed.
[1-16]
Save
Date
Job Title
City Country
State
Company Name
Pay
Nov 16
Administrative Assistant III
Morristown, USA
New Jersey
Watson Pharmaceuticals
Not specified
Nov 13
National Accounts Representative
Weston, USA
Florida
Watson Pharmaceuticals
Not specified
Nov 06
Chemist III
Fort Lauderdale, USA
Florida
Watson Pharmaceuticals
Not specified
Nov 06
Inside Sales Representative I
Grand Island, USA
New York
Watson Pharmaceuticals
Not specified
Nov 05
Manager, Drug Safety Systems
Corona, USA
California
Watson Pharmaceuticals
Not specified
Nov 04
Inside Sales Representative I
Corona, USA
California
Watson Pharmaceuticals
Not specified
Oct 30
Scientist Principal - Formulation
Davie, USA
Florida
Watson Pharmaceuticals
Not specified
Oct 30
R&D Technician III
Davie, USA
Florida
Watson Pharmaceuticals
Not specified
Oct 29
Pharm Tech Technician III
Davie, USA
Florida
Watson Pharmaceuticals
Not specified
Oct 29
Mfg Technician II
Davie, USA
Florida
Watson Pharmaceuticals
Not specified
Oct 29
Mfg Specialist I
Davie, USA
Florida
Watson Pharmaceuticals
Not specified
Oct 29
Benefits Analyst Sr.
Morristown, USA
New Jersey
Watson Pharmaceuticals
Not specified
Oct 29
Scientist Sr.
Davie, USA
Florida
Watson Pharmaceuticals
Not specified
Oct 26
Assoc Dir, Univ Relations & Inclusion
Morristown, USA
New Jersey
Watson Pharmaceuticals
Not specified
Sep 08
Mgr, Regulatory Affairs
Salt Lake City, USA
Utah
Watson Pharmaceuticals
Not specified
Aug 06
Manager, Engineering
Morristown, USA
New Jersey
Watson Pharmaceuticals
Not specified
